Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis

References

• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–11. doi:10.1056/NEJMoa1406498.
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the Percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535.
   PubMed Web of Science ®Google Scholar
• Konstantina T, Konstantinos R, Anastasios K, Anastasia M, Eleni L, Ioannis S, Sofia A, Dimitris M. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer. 2019;135:29–32. doi:10.1016/j.lungcan.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with Anti–Cytotoxic T-Lymphocyte Antigen-4. J Clin Oncol. 2005;23(25):6043–6053. doi:10.1200/JCO.2005.06.205.
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22):6681–6688. doi:10.1158/1078-0432.CCR-07-0187.
   PubMed Web of Science ®Google Scholar
• Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning Y-M, Singh H, Suzman D, Xu J, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death Ligand 1 Antibody. J Clin Oncol. 2019;37(30):2730–2737.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, Longo DL. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647. doi:10.1016/j.kint.2016.04.008.
   PubMed Web of Science ®Google Scholar
• Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68(2):287–291. doi:10.1053/j.ajkd.2016.02.057.
   PubMed Web of Science ®Google Scholar
• Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7(1):2. doi:10.1186/s40425-018-0478-8.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: a Multicenter Study. J Am Soc Nephrol. 2020;31(2):435–446.
   PubMed Web of Science ®Google Scholar
• Meraz-Munoz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C, Kim J, Wald R, Kitchlu A. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020;8(1):8. doi:10.1136/jitc-2019-000467.
   Web of Science ®Google Scholar
• Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani A-C, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–1700. doi:10.2215/CJN.00990119.
   PubMed Web of Science ®Google Scholar
• Ga M, Agraz I, Serón D, José SM. Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. Nephrol Dial Transplant. 2021. Pubmed: PMID 33547795.
   Web of Science ®Google Scholar
• Garcia-Carro C, Bolufer M, Bury R, Catañeda Z, Muñoz E, Felip E, Lorente D, Josep Carreras M, Gabaldon A, Agraz I, et al. Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. Nephrol Dial Transplant. 2021. doi:10.1093/ndt/gfab034.
   PubMed Web of Science ®Google Scholar
• Sparrow HG, Swan JT, Moore LW, Gaber AO, Suki WN. Disparate outcomes observed within Kidney Disease: improving Global Outcomes (KDIGO) acute kidney injury stage 1. Kidney Int. 2019;95(4):905–913. doi:10.1016/j.kint.2018.11.030.
   PubMed Web of Science ®Google Scholar
• Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu KD, Prowle JR, Shaw AD, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020;98(2):294–309. doi:10.1016/j.kint.2020.04.020.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117–1129. doi:10.1016/j.kint.2020.02.010.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988;16(3):1141–1154. doi:10.1214/aos/1176350951.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144.
   Web of Science ®Google Scholar
• Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–2430. doi:10.1002/sim.2712.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170.
   PubMedGoogle Scholar
• Cox DR. Regression Models and Life-Tables. J R Stat Soc B. 1972;34:187.
   Google Scholar
• Rizopoulos D. The R package jmbayes for fitting joint models for longitudinal and time-to-event data using MCMC. J Stat Softw. 2016;72(7):1–46. doi:10.18637/jss.v072.i07.
   Web of Science ®Google Scholar
• Cox D. Citation classic - regression-models and life-tables. Cc/Art Human. 1986;16(42):16-16.
   Google Scholar
• Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099. doi:10.1200/JCO.2014.60.0379.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME, Nishikawa H. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: a Systematic Review of Case Reports. PLoS One. 2016;11(7):e0160221. doi:10.1371/journal.pone.0160221.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017. Eur J Cancer. 2017;83:247–257. doi:10.1016/j.ejca.2017.06.028.
   PubMed Web of Science ®Google Scholar
• Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning Y-M, Singh H, Suzman D, Xu J, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death Ligand 1 Antibody. Journal of Clinical Oncology. 2019;37(30):2730.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo a secondary analysis of a randomized clinical trial. Jama Oncol. 2020;6(4):519–527. doi:10.1001/jamaoncol.2019.5570.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: a Multicenter Study. J Am Soc Nephrol. 2020;31(2):435–446.
   PubMed Web of Science ®Google Scholar
• Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, Patel A, Amaria RN, Giordano SH, Suarez-Almazor ME, et al. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. Journal of Clinical Oncology. 2016;34(15_suppl):3047. doi:10.1200/JCO.2016.34.15_suppl.3047.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29(8):2039–2052. doi:10.1681/ASN.2018050488.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med. 2018;169(2):133–134. doi:10.7326/L18-0209.
   PubMed Web of Science ®Google Scholar
• Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(6):610–616. doi:10.1016/j.autrev.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (Oxford). 2019;58(Supplement_7):vii40–vii8. doi:10.1093/rheumatology/kez297.
   PubMed Web of Science ®Google Scholar
• Shah M, Tayar JH, Abdel-Wahab/ N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2019;48(4):736–740. doi:10.1016/j.semarthrit.2018.05.006.
   PubMed Web of Science ®Google Scholar
• Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa’ak F, Saberian C, Yee C, Davies MA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. doi:10.1186/s40425-019-0774-y.
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren BY, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:7. doi:10.1038/ncomms10391.
   Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9.
   PubMedGoogle Scholar